Robin Park, MD

Dr. Park's research theme includes improving patient outcomes by developing effective novel immunotherapies and biomarkers.

Associations

• Head and Neck-Endocrine Oncology
• Immuno-Oncology Program

Dr. Park's research interests are in the development of effective treatment biomarkers and novel therapies with a focus on early-phase drug development.

Clinical Trial 23645
PHASE 1 DOSE ESCALATION AND EXPANSION STUDY OF XB628 AS A SINGLE AGENT AND IN COMBINATION WITH ZANZALINTINIB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Condition: Multiple
Intervention: XB628 (); Zanzalintinib ()
Status: Open

Clinical Trial 23647
A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
Condition: Head & Neck
Intervention: PYX-201 (); Pembrolizumab (Keytruda)
Status: Open

Clinical Trial 23829
A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants with Unresectable Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: TAK-505 ()
Status: Open

Clinical Trial 23965
A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single agent and in Combination with pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: BH3120 (); Pembrolizumab (Keytruda)
Status: Open

Clinical Trial 23993
A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMGS-001 in Patients with Relapsed or Refractory Advanced Solid Tumors
Condition: Multiple
Intervention: IMGS-001 ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Basharat A, Mannan MS, Shabbir MR, Khan MW, Basit T, Park R, Chadha J, Shahzad M. Transient PSA Suppression Without Survival Benefit: Real-World Comparative Effectiveness of Cabazitaxel Plus Carboplatin in Metastatic Castration-Resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2026 Jul.24(6):102625. Pubmedid: 42556088.
• Chaudhary R, Moorhead G, Park R, Li J, Schell MJ, Song X, Tan A, Slebos RJC, Biernacki MI, Freeman SS, Thatikonda S, Meshkovska Y, Hernandez-Prera J, Kirtane K, Guevara-Patino JA, Amelio AL, Rocco JW, Danysh BP, Bonomi M, Saba NF, Haradhvala NJ, Getz G, Chung CH. Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. Clin Cancer Res. 2026 Feb.32(3):501-515. Pubmedid: 41117857. Pmcid: PMC12667737.
• Park R, Rind F, Kristoff T, Li J, Schell M, Slebos RJC, Thatikonda S, Chaudhary R, Biernacki MI, Meshkovska Y, Kaldas D, Kim HS, Farinhas J, Hernandez-Prera J, Kirtane K, Hall MS, Amelio AL, Rocco JW, Bhateja P, Steuer C, Bonomi M, Saba NF, Chung CH. Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial. Am J Clin Oncol. 2026 Apr.49(4):176-187. Pubmedid: 40905435. Pmcid: PMC13011960.
• Lee WJ, Asghar MS, Park R, Won SH, Shahzad M, Shimshak T. Externally Validated Machine Learning Models for 30-/90-/180-Day Unplanned Readmission After Head and Neck Cancer Hospitalizations in the United States. JCO Clin Cancer Inform. 2026 Apr.10(2):e2500335. Pubmedid: 42284547. Pmcid: PMC13268123.
• Yu J, Laborde JM, Park R, Shahzad M, Kim Y, Cheon J, Imanirad I, Kim RD, Biachi de Castria T, Nardella NL, Malafa M, Denbo JW, Fleming JB, Hoffe SE, Frakes JM, Sinnamon AJ, Pimiento JM, Hodul PJ, Kim DW. Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Cancers (Basel). 2025 May.17(11). Pubmedid: 40507279. Pmcid: PMC12153592.
• Saeed A, Colby S, Oberstein PE, Duda DG, Park R, Agarwal R, Figueroa-Moseley C, Vaidya R, Unger JM, Guthrie KA, Rocha FG, Senthil M, Safyan RA, Wainberg ZA, Iqbal S, Chiorean EG, Philip PA. S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE). Future Oncol. 2025 May.21(11):1325-1331. Pubmedid: 40155326. Pmcid: PMC12051544.
• Echevarria M, Park R, Caudell JJ, Kim Y, Yang GQ, Kirtane K, Chaudhary R, Kumar S, Amelio AL, Giuliano AR, Chung CH. Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy. Cancer Res Commun. 2025 Jul.5(7):1194-1202. Pubmedid: 40643202. Pmcid: PMC12281097.
• Yu J, Park R, Tojjari A, Sadeghipour A, Saeed A, Saeed A. Zanzalintinib (XL092): a next-generation tyrosine kinase inhibitor-comprehensive review of early safety & efficacy data. Expert Opin Inv Drug. 2024 Sep.33(9):887-895. Pubmedid: 39099411.
• Yu J, Park R, Miao R, Imanirad I, Shahzad M, Laborde JM, Knepper TC, Walko CM, Kim R. Blood Tumor Mutational Burden Alone Is Not a Good Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Gastrointestinal Tumors. J Immunother. 2024 Nov.47(9):378-383. Pubmedid: 39012081.
• Shahzad M, Khalid MF, Amin MK, Basharat A, Ammad-Ud-Din M, Park R, Anwar I, Faisal MS, Jaglal M. Geographic and Racial Disparities in Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 May.24(5):316-322. Pubmedid: 38342727.
• Tojjari A, Park R, Yu J, Saeed A. Targeting Angiogenesis Alone and in Combination with Immune Checkpoint Inhibitors in Advanced Gastroesophageal Malignancies. Curr Gastroenterol Rep. 2024 Mar.26(3):57-67. Pubmedid: 38294661.
• Park R, Saeed A. Immunotherapy in Colorectal Cancer - Finding the Achilles' Heel. NEJM Evid. 2024 Jun.3(6):EVIDra2300353. Pubmedid: 38804784.
• Park R, Li J, Slebos RJC, Chaudhary R, Poole MI, Ferraris C, Farinhas J, Hernandez-Prera J, Kirtane K, Teer JK, Song X, Hall MS, Tasoulas J, Amelio AL, Chung CH. Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2024 Jul.154:106866. Pubmedid: 38820888.
• Saeed A, Park R, Pathak H, Al-Bzour AN, Dai J, Phadnis M, Al-Rajabi R, Kasi A, Baranda J, Sun W, Williamson S, Chiu YC, Osmanbeyoglu HU, Madan R, Abushukair H, Mulvaney K, Godwin AK, Saeed A. Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nat Commun. 2024 Feb.15(1):1533. Pubmedid: 38378868. Pmcid: PMC10879200.
• Park R, Yu J, Shahzad M, Lee S, Ji JD. The immune regulatory function of B7-H3 in malignancy: spotlight on the IFN-STAT1 axis and regulation of tumor-associated macrophages. Immunol Res. 2024 Aug.72(4):526-537. Pubmedid: 38265550.
• Yu J, Park R, Kim R. Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights. J Hepatocell Carcinoma. 2023 Jul.10:1105-1127. Pubmedid: 37483311. Pmcid: PMC10362916.
• Saeed A, Park R, Dai J, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Saeed A, Ripp J, Collins Z, Mulvaney K, Shugrue M, Firth-Braun J, Godwin AK, Madan R, Phadnis M, Sun W. Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results. Cell Rep Med. 2023 Feb.4(2):100916. Pubmedid: 36702123. Pmcid: PMC9975105.
• Riano I, Pomares-Millan H, Prasongdee K, Kiel L, Park R, Florez N. Evaluating Internal Medicine Residents' Awareness on Cancer Survivorship Care Plan: A Pilot Survey. J Community Hosp Intern Med Perspect. 2022 Nov.12(6):12-18. Pubmedid: 36816156. Pmcid: PMC9924639.
• Park R, Amin M, Trikalinos NA. Temozolomide duration and secondary hematological neoplasms: A literature review and implications for patients with neuroendocrine neoplasms. J Neuroendocrinol. 2022 Jul.34(7):e13178. Pubmedid: 35854663.
• Al-Jumayli M, Choucair K, Al-Obaidi A, Park R, Bansal A, Baranda J, Sun W, Saeed A. Pre-operative Carboplatin/Paclitaxel Versus 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer. Anticancer Res. 2022 Jan.42(1):59-66. Pubmedid: 34969709.
• Choucair K, Radford M, Bansal A, Park R, Saeed A. Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review). Int J Oncol. 2021 Sep.59(3). Pubmedid: 34396449. Pmcid: PMC8360619.
• Park R, Wulff-Burchfield E, Sun W, Kasi A. Is obesity a risk factor in cancer patients with COVID-19?. Future Oncol. 2021 Sep.17(27):3541-3544. Pubmedid: 34254528. Pmcid: PMC8276792.
• Oh Y, Park R, Kim SY, Park SH, Jo S, Kim TH, Ji JD. B7-H3 regulates osteoclast differentiation via type I interferon-dependent IDO induction. Cell Death Dis. 2021 Oct.12(11):971. Pubmedid: 34671026. Pmcid: PMC8528854.
• Park R, Lopes L, Lee S, Riano I, Saeed A. The prognostic and predictive impact of BRAF mutations in deficient mismatch repair/microsatellite instability-high colorectal cancer: systematic review/meta-analysis. Future Oncol. 2021 Nov.17(31):4221-4231. Pubmedid: 34323124.
• da Silva LL, Aguiar PN, Park R, Edelman Saul E, Haaland B, de Lima Lopes G. Comparative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Network Meta-Analysis of Phase III Clinical Trials. Cancers (Basel). 2021 May.13(11). Pubmedid: 34073475. Pmcid: PMC8199431.
• Park R, Lopes da Silva L, Nissaisorakarn V, Riano I, Williamson S, Sun W, Saeed A. Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials. J Hepatocell Carcinoma. 2021 Mar.8:145-154. Pubmedid: 33791250. Pmcid: PMC7997949.
• Park R, Coveler AL, Cavalcante L, Saeed A. GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties. Biology (Basel). 2021 Jul.10(7). Pubmedid: 34356465. Pmcid: PMC8301062.
• Park R, Lopes L, Saeed A. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis. Clin Transl Oncol. 2021 Jan.23(1):100-109. Pubmedid: 32495269.
• Milla-Godoy GC, Park R, Jiang W, Hartkopf MW, Treadwell T. Fulminant COVID-19-Associated Myocarditis in an Otherwise Healthy Female. Cureus. 2021 Jan.13(1):e12736. Pubmedid: 33614338. Pmcid: PMC7883749.
• Park R, Lee SA, Kim SY, de Melo AC, Kasi A. Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data. Acta Oncol. 2021 Jan.60(1):13-19. Pubmedid: 33131376.
• Saeed A, Park R, Sun W. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials. J Hematol Oncol. 2021 Jan.14(1):13. Pubmedid: 33436042. Pmcid: PMC7802258.
• Park R, Al-Jumayli M, Miller K, Saeed A, Saeed A. Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma. Cancer Treat Res Commun. 2021 Feb.27:100342. Pubmedid: 33611092.
• Madala S, MacDougall K, Surapaneni BK, Park R, Girotra M, Kasi A. Coinfection of Helicobacter pylori and Hepatitis C Virus in the Development of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. J Clin Med Res. 2021 Dec.13(12):530-540. Pubmedid: 35059071. Pmcid: PMC8734513.
• Park R, Park JC. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer. Immunotherapy. 2021 Aug.13(11):931-940. Pubmedid: 34100301.
• Park R, Da Silva LL, Saeed A. Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond. Cancers (Basel). 2021 Apr.13(7). Pubmedid: 33916348. Pmcid: PMC8038572.
• Park R, Chidharla A, Mehta K, Sun W, Wulff-Burchfield E, Kasi A. Sex-bias in COVID-19-associated illness severity and mortality in cancer patients: A systematic review and meta-analysis. EClinicalMedicine. 2020 Sep.26:100519. Pubmedid: 32864589. Pmcid: PMC7445555.
• Park R, Madhavaram S, Ji JD. The Role of Aryl-Hydrocarbon Receptor (AhR) in Osteoclast Differentiation and Function. Cells. 2020 Oct.9(10). Pubmedid: 33066667. Pmcid: PMC7602422.
• Park R, Lopes L, Saeed A. Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis. Immunotherapy. 2020 Nov.12(16):1183-1193. Pubmedid: 32878511.
• Cristancho C, Riano I, Guareras-Paredes D, Park R, Seetharaman K. Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab. Cureus. 2020 May.12(5):e8072. Pubmedid: 32542127. Pmcid: PMC7290116.
• Park R, Lopes L, Cristancho CR, Riano IM, Saeed A. Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. Front Oncol. 2020 Mar.10:258. Pubmedid: 32257944. Pmcid: PMC7090167.
• Park R, Lopes L, Saeed A. Association Between the Functional miR-146a SNP rs2910164 and Risk of Digestive System Cancer: Updated Meta-analysis. Anticancer Res. 2020 Mar.40(3):1495-1502. Pubmedid: 32132049.
• Park R, Philp A, Nagji AS, Kasi A. Pathologically Complete Response after Triple Therapy in Locally Advanced Esophageal Cancer in a Hereditary Hemorrhagic Telangiectasia Patient. Case Rep Oncol. 2020 Feb.13(1):176-181. Pubmedid: 32231541. Pmcid: PMC7098335.
• Kasi A, Al-Jumayli M, Park R, Baranda J, Sun W. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review. J Pancreat Cancer. 2020 Dec.6(1):107-115. Pubmedid: 33376937. Pmcid: PMC7757687.
• Park R, Umar S, Kasi A. Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials. Curr Colorectal Cancer Rep. 2020 Aug.16(4):81-88. Pubmedid: 32607098. Pmcid: PMC7325521.
• Saeed A, Hameem ZU, Modi D, Park R, Saeed A. Cutaneous paraneoplastic syndrome associated with anal squamous cell carcinoma: a rare presentation of an uncommon cancer. Curr Oncol. 2020 Aug.27(4):e433-e435. Pubmedid: 32905348. Pmcid: PMC7467788.
• Park R, Eshrat F, Al-Jumayli M, Saeed A, Saeed A. Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. Vaccines (Basel). 2020 Aug.8(3). Pubmedid: 32784389. Pmcid: PMC7563532.
• Saeed A, Park R, Al-Jumayli M, Al-Rajabi R, Sun W. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma. Clin Colorectal Cancer. 2019 May.18(2):81-90. Pubmedid: 30905548.
• Park R, Williamson S, Kasi A, Saeed A. Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer. Anticancer Res. 2018 Oct.38(10):5569-5580. Pubmedid: 30275174.
• Park R, Lee WJ, Ji JD. Association between the three functional miR-146a single-nucleotide polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: A meta-analysis. Autoimmunity. 2016 Nov.49(7):451-458. Pubmedid: 27098222.
• Park R, Ji JD. Calcium channels: the potential therapeutic targets for inflammatory bone destruction of rheumatoid arthritis. Inflamm Res. 2016 May.65(5):347-354. Pubmedid: 26852086.
• Park R, Ji JD. Unique gene expression profile in osteoarthritis synovium compared with cartilage: analysis of publicly accessible microarray datasets. Rheumatol Int. 2016 Jun.36(6):819-827. Pubmedid: 26942917.
• Marton J, Albert D, Wiltshire SA, Park R, Bergen A, Qureshi S, Malo D, Burelle Y, Vidal SM. Cyclosporine A Treatment Inhibits Abcc6-Dependent Cardiac Necrosis and Calcification following Coxsackievirus B3 Infection in Mice. PLoS One. 2015 Sep.10(9):e0138222. Pubmedid: 26375467. Pmcid: PMC4574283.